Annual report
4483.TEDINET S100YJCA
Period2025-04-01 → 2026-03-31
Filed2026-06-24
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 155
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥50.5bn | 2025-04-01 → 2026-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥41.7bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥30.6bn | 2023-04-01 → 2024-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥27.8bn | 2022-04-01 → 2023-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥21.8bn | 2021-04-01 → 2022-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥10.5bn | 2025-04-01 → 2026-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥8.7bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥10.0bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥8.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥5.4bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥5.9bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥4.8bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥6.8bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥7.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥4.6bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥4.3bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥3.2bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥6.8bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥7.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥158.5bn | at 2026-03-31 | Cons. | Assets IFRS |
| Total assets | ¥143.0bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥122.5bn | at 2024-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥98.6bn | at 2023-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥62.1bn | at 2022-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥74.4bn | at 2026-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥64.5bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥84.2bn | at 2026-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥78.5bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥70.7bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥83.7bn | at 2026-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥78.0bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥70.6bn | at 2024-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥64.5bn | at 2023-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥31.2bn | at 2022-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥28.9bn | at 2026-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥32.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.5bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥22.8bn | at 2023-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥13.2bn | at 2022-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥8.6bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥14.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥17m | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥4.1bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥3.8bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥10.6bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥3.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥24.9bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥22.8bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥8.1bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥1.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥16.6bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥28.3bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥103.44 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥111.34 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥71.76 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥71.17 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥57.74 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥102.46 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥110.23 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥69.95 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥67.69 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥54.16 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,278.09 | at 2026-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,192.97 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,080.51 | at 2024-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,025.89 | at 2023-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥551.17 | at 2022-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 52.8% | at 2026-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 54.6% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 57.6% | at 2024-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 65.5% | at 2023-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.2% | at 2022-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 8.4% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 9.8% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.8% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 8.9% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 10.9% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 2,444 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 2,187 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 1,773 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 1,346 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 966 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥14.4bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥12.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥11.5bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥9.4bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥8.0bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥1.1bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥696m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.0bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.1bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.9bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.8bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.7bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥598m | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥4.1bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | −¥124m | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥3.1bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | −¥429m | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.3bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.2bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥103.6bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥103.9bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥90.9bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥73.2bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥41.4bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥41.2bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥40.3bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥62.4bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥63.6bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥60.9bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥59.8bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥29.3bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.9bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.3bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-1.9 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥47.56 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.69 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.08 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.54 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥47.08 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥21 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥20.2 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥18 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥16 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥10 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥952.57 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥972.76 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥931.64 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥950.74 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥517.6 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 60.2% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.2% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.0% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.7% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.7% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -0.2% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -0.7% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 65,439,808 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 65,373,808 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 65,331,208 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 62,910,608 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 56,514,208 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 499 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 488 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 431 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 348 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 305 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 27
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥952m |
| Healthcare Big Datareportable segment | employees | at 2026-03-31 | 2303 pure |
| Healthcare Big Datareportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥44.1bn |
| Healthcare Big Datareportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥44.1bn |
| Healthcare Big Datareportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥11.7bn |
| Tele Medicinereportable segment | employees | at 2026-03-31 | 138 pure |
| Tele Medicinereportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥6.4bn |
| Tele Medicinereportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥6.4bn |
| Tele Medicinereportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥2.4bn |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥50.5bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥50.5bn |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥14.1bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥41m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥41m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥861m |
| Healthcare Big Datareportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥35.6bn |
| Healthcare Big Datareportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥35.6bn |
| Healthcare Big Datareportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥41m |
| Healthcare Big Datareportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥9.6bn |
| Tele Medicinereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| Tele Medicinereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| Tele Medicinereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥2.2bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥41.8bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥41.7bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥41m |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥11.8bn |
| Healthcare Big Datareportable segment | employees | at 2026-03-31 | 499 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,757
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 499 | |
| Average number of temporary workers | Prior4YearInstant_NonConsolidatedMember | 31 | |
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | 29 | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 27 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 34 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 43 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 1.297 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.876 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.698 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.539 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.634 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.020 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.079 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.525 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.502 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.170 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 30 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 21 | |
| Research and development expenses research and development activities | CurrentYearDuration | 126000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 76000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E35308-000TeleMedicineReportableSegmentMember | 49000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 3812000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 3371000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E35308-000TeleMedicineReportableSegmentMember | 441000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 65439808 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 65443808 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 65439808 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 65443808 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 14 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 28 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 74 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 195 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 50 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 7639 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 8000 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 85182 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 8917 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 385609 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 115232 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 460 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 58711 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 654111 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 28708 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.1302 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0136 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.5895 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |